byiShook Opinion
Mar 28, 2025 - 11:20
Novo Nordisk will pay Lexicon $1 billion up front to license its experimental obesity treatment. The news sent penny stock Lexicon flying. The post Novo Nordisk Inks Its Second Big Obesity Deal In A Week — And It's Not For A GLP-1 appeared first on Investor's Business Daily.
Novo Nordisk will pay Lexicon $1 billion up front to license its experimental obesity treatment. The news sent penny stock Lexicon flying.
The post Novo Nordisk Inks Its Second Big Obesity Deal In A Week â And It's Not For A GLP-1 appeared first on Investor's Business Daily.